Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US

Overview of attention for article published in Frontiers in Pharmacology, August 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 1 X post from an account with 5,875 followers.

New Research: Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US https://t.co/vzduociUzJ #FrontiersIn #Pharmacology

14 Aug 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.